Inmune Bio INMB

INmune Bio is a clinical stage biotechnology company dedicated to developing and commercializing product candidates that reprogram the innate immune system. The company focuses on diseases where chronic inflammation and immune dysfunction are primary drivers of pathology. Its lead program is CORDStrom a pooled human umbilical cord derived mesenchymal stromal cell therapy intended for the treatment of recessive dystrophic epidermolysis bullosa. In addition INmune Bio advances two other platforms XPro1595 which targets neuroinflammation in Alzheimer disease and INKmune a natural killer cell priming agent for oncology indications. The company is headquartered in the United States with manufacturing activities based in the United Kingdom.

INmune Bio currently generates limited revenue because its product candidates remain in clinical development. Revenue streams arise from compensation received for supplying investigational material to clinical trial sites from licensing agreements and from potential milestone payments tied to regulatory achievements. The company has received payments for providing CORDStrom to hospitals participating in the MissionEB study and holds license agreements that may yield future royalties and milestone fees upon commercialization. No product sales have been realized to date as all candidates are still awaiting marketing authorization.

The company operates through the following segments: CORDStrom XPro and INKmune.

• CORDStrom segment encompasses the proprietary pooled human umbilical cord derived mesenchymal stromal cell platform. The product is manufactured off the shelf under current good manufacturing practices in the United Kingdom. It is being developed primarily for recessive dystrophic epidermolysis bullosa a rare pediatric disease characterized by severe skin blistering and systemic complications. Clinical data from a pivotal blinded randomized crossover trial showed reductions in itch pain and improvements in wellbeing. The company plans to submit a marketing authorization application in the United Kingdom in July 2026 in the European Union in September 2026 and a biologics license application with the U S Food and Drug Administration in December 2026.

• XPro segment focuses on the DN TNF platform technology that produces a next generation protein therapeutic designed to selectively neutralize soluble tumor necrosis factor. The lead candidate XPro1595 is being evaluated for the treatment of Alzheimer disease with an emphasis on neuroinflammation. XPro completed a phase I trial demonstrating brain penetration and reduction of cerebrospinal fluid biomarkers of inflammation. A phase II randomized double blind placebo controlled study enrolled patients across sites in the United Kingdom European Union Australia Canada and other countries. While the primary cognitive endpoint was not met in the overall population a prespecified subgroup enriched for inflammatory biomarkers showed an effect size exceeding the company threshold for clinical relevance on cognition and neuropsychiatric symptoms.

• INKmune segment consists of a natural killer cell priming platform that converts resting NK cells into memory like cells capable of killing tumor cells. The product is being investigated in metastatic castrate resistant prostate cancer through an open label phase I II trial conducted in the United States. Prior work in high risk myelodysplastic syndrome and acute myeloid leukemia demonstrated safety and induction of cancer killing memory like NK cells that persisted in circulation for up to four months after treatment. The company does not intend to advance INKmune further into later stage development at present due to capital constraints.

INmune Bio occupies a niche within the broader biotechnology industry by concentrating on innate immune modulation rather than adaptive immunity approaches. Competitors include companies developing mesenchymal stromal cell therapies anti TNF biologics and NK cell engagers for oncology. The firm’s competitive advantages stem from its proprietary platform technologies orphan drug designations for CORDStrom which may confer seven years of market exclusivity and eligibility for a priority review voucher if approved by the FDA before September 2029. Additionally the company holds a broad patent portfolio covering compositions formulations and methods of use for each of its three platforms providing a barrier to entry for potential rivals.

The company’s customer base consists of patients suffering from rare inflammatory neurodegenerative and oncologic conditions as well as the healthcare institutions that treat them. Specific customers identified in the filing include Great Ormond Street Hospital and Birmingham Children’s Hospital in the United Kingdom where CORDStrom was supplied for the MissionEB study. Broader customer groups comprise pediatric patients with recessive dystrophic epidermolysis bullosa individuals with early Alzheimer disease exhibiting neuroinflammatory biomarkers and patients with metastatic castrate resistant prostate cancer. INmune Bio also engages with academic collaborators and contract manufacturing organizations to support preclinical and clinical activities.